Displaying 341 - 360 of 676
FTC Challenges Consummated Merger of Companies That Make Microprocessor Prosthetic Knees
FTC Alters Final Consent Order in Response to Public Comments, Preserving Competition for Specialty and Emergency Veterinary Services in 10 U.S. Localities
FTC Requires Retail Fuel Station and Convenience Store Operator Alimentation Couche-Tard Inc. and its affiliate CrossAmerica Partners LP to Divest 10 Fuel Stations in Minnesota and Wisconsin as a Condition of Acquiring Holiday Companies
Statement by Federal Trade Commission Acting Bureau of Competition Director Bruce Hoffman on the Court Ruling Granting a Preliminary Injunction in the Sanford Health/Mid Dakota Clinic Matter
FTC Challenges Proposed Merger of Major Titanium Dioxide Companies
FTC Requires Retail Fuel Station and Convenience Store Operator Alimentation Couche-Tard Inc. to Divest 3 Fuel Stations in Alabama as a Condition of Acquiring Jet-Pep, Inc.
FTC Approves Final Order Preserving Competition in the U.S. Markets for Two Types of Medical Testing Devices
Parties Agree to Divestiture of Senior Living Facilities Referral Service Caring.com as a Condition of Red Venture’s Acquiring Bankrate
FTC Seeks Public Comment on Fresenius Medical Care AG’s Application for Approval of Proposed Plan to Establish New Outpatient Hemodialysis Clinic
Statement of Acting Chairman Maureen K. Ohlhausen In Walgreens Boots Alliance/Rite Aid
Grifols, S.A., and Talecris Biotherapeutics Holdings Corp., In the Matter of
The FTC required Grifols, S.A., a manufacturer of plasma-derived drugs, to make significant divestitures as part of a settlement allowing Grifols to acquire a leading plasma-derived drug manufacturer, Talecris Biotherapeutics Holdings Corp. It resolves FTC charges that Grifols’ proposed acquisition of Talecris would be anticompetitive and would violate federal antitrust laws. As part of the settlement, Grifols will sell the Talecris fractionation facility in Melville, New York, and Grifols’ plasma collection centers in Mobile, Alabama, and Winston-Salem, North Carolina, to Kedrion S.p.A. Kedrion is a manufacturer of plasma-derived products in Europe and other markets, and will be a new entrant in the U.S. plasma-derived products industry. Grifols also will manufacture three plasma-derived products for Kedrion for several years under a manufacturing agreement. The FTC approved a final order on July 22, 2011.
FTC Approves Final Order Requiring Divestitures of Retail Fuel Stations and Convenience Stores Related to Alimentation Couche-Tard Inc.’s Merger with Competitor CST Brands, Inc.
Doctors Hospital at Renaissance/Mission Regional Medical Center
FTC Staff Provides Additional Comment and Testimony in Tennessee Opposing Mountain States’ and Wellmont’s Certificate of Public Advantage Application
Wellmont Health System/Mountain States Health Alliance
FTC Requests Public Comment on Application from Grifols, S.A. to Amend Contract Manufacturing Agreement that was part of 2011 Divestiture Ordered by the Agency
FTC Requires Retail Fuel Station and Convenience Store Operator Alimentation Couche-Tard Inc. to Divest up to 71 Fuel Stations as a Condition of Merger with Competitor CST Brands, Inc.
FTC and State Attorney General Challenge Physician Group Acquisition in North Dakota
Displaying 341 - 360 of 676